Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plinabulin - BeyondSpring Pharmaceuticals

Drug Profile

Plinabulin - BeyondSpring Pharmaceuticals

Alternative Names: BPI 2358; NPI 2358

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer BeyondSpring Pharmaceuticals; Big Ten Cancer Research Consortium; National Cancer Institute (USA); Nereus Pharmaceuticals; Rutgers Cancer Institute of New Jersey; University of Washington
  • Class Antineoplastics; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action Guanine nucleotide exchange factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neutropenia; Non-small cell lung cancer
  • Phase I/II Small cell lung cancer
  • No development reported Brain cancer; Glioblastoma; Solid tumours

Most Recent Events

  • 23 Oct 2019 BeyondSpring announces intention to submit a NDA to China’s National Medical Products Administration (NMPA) for chemotherapy-induced Neutropenia and Non-small cell lung cancer in first quarter of 2020
  • 23 Oct 2019 BeyondSpring announces intention to submit the NDA to US FDA for chemotherapy induced Neutropenia and Non-small cell lung cancer in year 2020
  • 17 Oct 2019 BeyondSprings Pharmaceuticals has patent protection for plinabulin for the treatment of Glioblastoma multiforme and other brain tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top